News
In July 2025, Novartis Pharmaceuticals conducted a study is to assess the effect of Iptacopan to prevent conversion of early ...
In July 2025, Novartis Pharmaceuticals organized a study is to assess the effect of Iptacopan to prevent conversion of early ...
An oral presentation by David Eichenbaum, M.D., Director of Research at the Retina Vitreous Associates of Florida on the design and rationale of the pivotal Phase 3 ARCHER II trial will take place on ...
The presentation, “OpRegen® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 36 Results from the Phase 1/2a Trial,” was presented by Christopher ...
Incomplete RPE and outer retinal atrophy [iRORA] in intermediate AMD and larger RPE atrophy in GA were both associated with increased CCFD% (P<0.001). Investigators concluded that CCFD% increased with ...
Cognition Therapeutics presented preclinical data on zervimesine's potential to protect retinal cells in dry AMD at ARVO.
Eyestem Research announced positive results from its phase 1 trial (NCT06394232) evaluating its investigational drug product, Eyecyte-RPE, in patients with geographic atrophy (GA) secondary to dry age ...
Access free, up-to-date clinical references regarding the clinical examination and imaging of geographic atrophy. Healio's Clinical Guidance content provides valuable insights for physicians.
Access free, up-to-date clinical references on differential diagnosis and diagnostic criteria for geographic atrophy. Healio's Clinical Guidance content provides valuable insights for physicians.
Among patients diagnosed with intermediate-stage age-related macular degeneration, a fair number of eyes in a new analysis showed evidence of geographic atrophy (GA), a leading cause of blindness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results